If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() Chemical Biology & Drug DesignVolume 69 Issue 1, Pages 5 - 13 Published Online: 29 Jan 2007 © 2010 John Wiley & Sons A/S
Abstract | References | Full Text: HTML, PDF (Size: 660K) | Supporting Information | Related Articles | Citation Tracking Research Article Binding Pathways of Ligands to HIV-1 Protease: Coarse-grained and Atomistic Simulations Copyright 2007 The Authors Journal compilation 2007 Blackwell Munksgaard KEYWORDS association rate • binding kinetics • drug design • gating effects ABSTRACTMultiscale simulations (coarse-grained Brownian dynamics simulations and all-atom molecular dynamics simulations in implicit solvent) were applied to reveal the binding processes of ligands as they enter the binding site of the HIV-1 protease. The initial structures used for the molecular dynamics simulations were generated based on the Brownian dynamics trajectories, and this is the first molecular dynamics simulation of modeling the association of a ligand with the protease. We found that a protease substrate successfully binds to the protein when the flaps are fully open. Surprisingly, a smaller cyclic urea inhibitor (XK263) can reach the binding site when the flaps are not fully open. However, if the flaps are nearly closed, the inhibitor must rearrange or binding can fail because the inhibitor cannot attain proper conformations to enter the binding site. Both the peptide substrate and XK263 can also affect the protein's internal motion, which may help the flaps to open. Simulations allow us to efficiently study the ligand binding processes and may help those who study drug discovery to find optimal association pathways and to design those ligands with the best binding kinetics. Received 29 November 2006, revised 13 December 2006, accepted for publication 19 December 2006 |